Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is an outpatient consulting a psychiatrist.~* The patient has a recurrent Major Depressive Disorder diagnosed according to DSM-IV-TR™. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient had at least one previous MDE before the age of 60 years.~* The patient has a moderate to severe depression and an insufficient response to at least one and no more than three adequate antidepressants treatments.~* The patient, if a woman, must have had her last natural menstruation ≥24 months prior to the Screening Visit.~* The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential.~Exclusion Criteria:~* The patient has any current psychiatric disorder or Axis I disorder (DSM-IV-TR™ criteria), established as the primary diagnosis, other than MDD.~* The patient has a current Axis II (DSM-IV-TR™) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypical or histrionic personality disorder.~* The patient has experienced/experiences hallucinations, delusions or any psychotic symptomatology in the current MDE.~* The patient suffers from mental retardation, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).~* The patient, in the opinion of the investigator, or according to Columbia Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.~* The patient has had neuroleptic malignant syndrome.~* The patient has any relevant medical history or current presence of systemic disease.~* The patient has a neurodegenerative disorder.~* The patient has, at the Screening Visit an abnormal ECG that is, in the investigator's opinion, clinically significant.~* The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for \>5 years prior to the first dose of IMP.~* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
- Brexpiprazole 1 mg (Type: EXPERIMENTAL): Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
- Brexpiprazole 3 mg (Type: EXPERIMENTAL): Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).